Innovative Therapeutic Solutions to Treat Obesity and Related Indications
Brite Therapeutics is a Delaware-based company whose mission is to develop new treatments for obesity and related metabolic disorders. We are 1) exploiting brown and brite fat cell biology to identify new drug targets and support new drug discovery and we are 2) progressing a novel combination of repurposed drugs (aka Brite-1) to treat obesity, fatty liver disease, and related metabolic complications. We are interested in strategic partnerships using our proprietary brite/brown cells to support target and drug discovery and we are seeking investments to initiate clinical trials for treating obesity.
Walid Kuri-Harcuch, PhD, Founder, CEO & CSO
Work Experience: Cinvestav, Celadon Science (Advanced Biohealing), Biosurface Technology
Scott H Gillis, MBA, Founder, Chief Business Officer
Work Experience: Massachusetts Biotechnology Council, Nucryst Pharma, BMS
JD Bernardy, JD, Chief Regulatory & Quality Officer
Work Experience: Boston Biomedical, Aeris Therapeutics, Dupont Pharma
Cristina Velez-delValle, PhD, Molecular Biology Research
Work Experience: Cinvestav, UNAM
James M Lenhard, PhD, Chief Pharmaceutical Research Officer
Work Experience: Assist Panacea, Janssen Pharmaceutical Companies of Johnson & Johnson, GlaxoSmithKline
Our Team
Click for LinkedIn
PUBLICATIONS
Gene expression and characterization of clonally derived murine embryonic brown and brite adipocytes. Cristina Velez-delValle, Claudia Patricia Hernandez-Mosqueira, Lidia Itzel Castro-Rodriguez, Alfredo Vazquez-Sandoval, Meytha Marsch-Moreno, Walid Kuri-Harcuch https://febs.onlinelibrary.wiley.com/doi/10.1002/2211-5463.13861
Location
Brite Therapeutics, Inc. is incorporated in Delaware, USA. Our team is dedicated to advancing novel drug combinations for metabolic diseases.
Contact
Mon-Fri 9am-5pm